Pantoprazole does not interact with nifedipine in man under steady-state conditions

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 2, 1996, Pages 51-55

  Bliesath, H ^a,c   Huber, R ^a   Steinijans, V W ^a   Koch, H J ^a   Kunz, K ^b   Wurst, W ^a  

^a ALTANA PHARMA AG   (Germany)

^b Inst fur Bioanalytische Forschung   (Germany)

^c Byk Gulden   (Germany)

Author keywords

Calcium antagonist; Interaction; Nifedipine; Pantoprazole; Proton pump inhibitor

Indexed keywords

CALCIUM ANTAGONIST; CYTOCHROME P450; NIFEDIPINE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; HEADACHE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; LIVER METABOLISM; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; STOMACH ACID SECRETION; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; LIVER; MALE; NIFEDIPINE; OMEPRAZOLE; SULFOXIDES;

EID: 0030042688     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Adams LJ, Antonow DR, McClain CJ, McAllister R 1986 Effect of ranitidine on bioavailability of nifedipine. Gastroenterology 90: 1320
2. Belz GG, Bliesath H, Essig J, Neumann N, Zech K, Wurst W 1992 Differential effects of two dihydropyridine calcium antagonists in humans. Clin Pharmacol Ther 52: 68-79
3. Bliesath H, Huber R, Hartmann M, Steinijans VW, Koch H, Wurst W 1995 Pantoprazole does not interact with diclofenac. Gastroenterol 108 (Suppl.): A61
4. Danhof M, Soons PA, van den Berg G, van Brummelen P, Jansen JBMJ, Lamers CBHW, Breimer DD 1989 Interaction between Nifedipine and Omeprazole. Eur J Clin Pharmacol 36 (Suppl.): 11.01
5. De Mey C, Meineke I, Steinijans VW, Huber R, Hartmann M, Bliesath H, Wurst W 1994 Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharmacol Ther 32: 98-106
6. Dilettt E, Hauschke D, Steinijans VW 1991 Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29: 1-8
7. Dokladalova J, Tykal JA, Coco SJ, Durkee PE, Quercia GT, Korst JJ 1982 Occurrence and measurement of nifedipine and its nitropyridine derivates in human blood plasma. J Chromatogr 231: 451-454
8. Duursema L, Müller FO, Schall R, Middle MV, Hundt HKL, Groenewoud G, Steinijans VW, Bliesath H 1995 Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 39: 700-703
9. Dylewicz P, Kirch W, Ohnhaus EE 1987 Wechselwirkung von Nifedipin mit Ranitidin und Cimetidin. Therapiewoche 37: 4837-4842
10. Ehrlich A, Fuder H, Hartmann M, Timmer W, Huber R, Birkel M, Bliesath H, Steinijans VW, Wurst W 1995 Lack of pharmacokinetic and pharmacodynamic interaction of pantoprazole and phenprocoumon in man. Gastroenterol 108 (Suppl.): A86
11. Gugler R, Jensen JC 1985 Omeprazole inhibits oxidative drug metabolism-studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 89: 1235-1241
12. Gugler R, Jensen JC 1987 Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther Vol. 33: 133-137
13. Gugler R, Hartmann M, Rudi J, Bliesath H, Brod I, Klotz U, Huber R, Steinijans VW, Wurst W 1992 Lack of interaction of pantoprazole and diazepam in men. AGA meeting 1992, San Francisco, USA. Gastroenterology 702 (Suppl.): A77
14. Guengerich FP, Böcker RH 1988 Cytochrome P450-catalyzed dehydro genation of 1,4-dihydropyridines. J Biol Chem 263: 8168-8175
15. Guengerich FP, Martin MV, Beaune PH, Kremer P, Wolff T, Waxmann DJ 1986 Characterization of rat and human liver microsomal cytochrome P450 involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 207: 5051-5060
16. Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Berntsson P 1991 Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P450 IIIA4. J Med Chem 34: 1838-1844
17. +-ATPase inhibitor pantoprazole (BY1023/ SK&F96022) compared to other antiulcer drugs. Meth Find Exp Clin Pharmacol 13: 63-67
18. Hartmann M, Bliesath H, Zech K, Koch H, Steinijans VW, Wurst W, Mascher H 1995a Pantoprazole does not influence CYPIA2 activity in man. Gastroenterol 108 (Suppl): A109
19. Hartmann M, Huber R, Bliesath H, Steinijans VW, Koch HJ, Wurst W 1995b Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther 33: 481-485
20. Huber R. Müller W, Banks MC, Rogers SJ, Norwood PC, Doyle E 1990 High performance liquid chromatographic determination of the H+/K+-ATPase inhibitor (BY 1023/SK&F96022) and its sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean up. J Chromatogr 529: 289-401
21. Judmaier G, Koelz HR 1994 The pantoprazole-duodenal ulcer-study group. Aliment Pharmacol Ther 8: 81-86
22. Kleinbloesem CH, van Brummelen P, Breimer DD 1987 Nifedipine: relationship between pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 12: 12-29
23. Kleinbloesem CH, van Brummelen P, Faber H, Breimer DD 1987 Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients. J Cardiovasc Pharmacol 9: 202-208
24. Koch HJ, Hartmann M, Bliesath H, Huber R, Steinijans VW, Mascher H, Wurst W 1996 Pantoprazole does not influence metoprolol pharmacokinetics and pharmacodynamics in man. Gastroenterology (in press)
25. Kromer W, Postius S, Riedel R, Simon WA, Hanauer G, Bran U, Gonne S, Parsons ME 1990 BY1023/SK&f96022, INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion hut lacks relevant cytochrome P450 interactions. J Pharmacol Exp Therap 29: 369-375
26. Middle MV, Müller FO, Schall R, Groenewoud G, Hundt HKL, Huber R, Bliesath H, Steinijans VW 1995a No influence of pantoprazole on the pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther 33: 304-307
27. Middle MV, Müller FO, Schall R, Hundt HKL, Mogilnicka EM, Beneke PC 1995b. Effect of pantoprazole on ovulation suppression by a low-dose hormonal contraceptive. Clin Drug Invest 9: 54-56
28. Müller P, Simon B, Khalil H, Luhmann R, Leucht U, Schneider A 1992 Dose range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Z Gastroenterol 30: 771-775
29. Naidu MUR, Shobha JC, Dixit VK, Kumar A, Kumar TR, Sekhar KR, Sekhar EC 1994 Effect of multiple dose omeprazole on the pharmacokinetics of carbamazepine. Drug Invest 7: 8-12
30. Pietta P, Rava A, Biondt P 1981 High-performance liquid chromatography of nifedipine its metabolites and photochemical degradation products. J Chromatogr 270: 516-552
31. Sauter R, Steinijans VW, Duletti E, Böhm A, Schulz H-U 1992 Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 30: 233-256
32. Schulz HU, Hartmann M, Steinijans VW, Huber R, Lührmann B, Bliesath H, Wurst W 1991 Lack of influence of pantoprazole on the disposition kinetics of theophylline in man Int J Clin Pharmacol Ther Toxicol 29: 369-375
33. +-ATPase inhibitor BY1023/SK&F96022 - inhibition of pentagastrin - stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 4: 239-245
34. +-ATPase inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. Z Gastroenterol 28: 443-447
35. Soons PA, van den Berg G, Danhof M, van Brummelen P, Jansen JBMJ, Lamers CBHW, Breimer DD 1992 Influence of single-and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol 42: 319-324.
36. Sreinijans VW, Hartmann M, Huber R. Radtke HW 1991 Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 29, 323-328
37. Surfin T, Balmer K, Bostrom H, Erikson S, Höglund P, Paulsen O 1989 Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 11: 176-184
38. Tucker GT 1994 The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 8 (Suppl. 1): 33-38